IL-1β-Triggered Long Non-coding RNA CHRF Induces Non-Small Cell Lung Cancer by Modulating the microRNA-489/Myd88 Axis

Zhang, Yamei; Zhang, Yabo; Zeng, Qianglin; Li, Ci; Zhou, Hui; Liu, Junying; Shi, Zheng; Ma, Li

doi:10.7150/jca.63256

Cited by 2 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…International Publisher [10][11][12][13][14]. LncRNAs have been found to be involved in a variety of biological processes, can act as oncogenes or tumor suppressors, and are associated with various aspects of cancer, including tumorigenesis, metastasis, and treatment resistance [15][16][17][18][19]. The aberrant expression patterns of lncRNAs in GI cancers have been linked to clinical outcomes, making them promising tumor markers and potential therapeutic targets [11,[20][21][22][23][24][25][26].…”

Section: Ivyspringmentioning

confidence: 99%

LncRNA-MUF: A Novel Oncogenic Star with Potential as a Biological Marker and Therapeutic Target for Gastrointestinal Malignancies

Wang,

Zhang

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers pose a significant global health challenge, characterized by a high incidence and poor prognosis. The delayed detection and occurrence of metastasis contribute to the overall low survival rates associated with these cancers. Therefore, there is an urgent need to identify novel molecular targets for effective GI cancer treatment. Recent research has shed light on the potential of long non-coding RNAs (lncRNAs) as promising targets in cancer therapy, given their strong association with carcinogenesis and profound impact on tumor development. Among these lncRNAs, lncRNA-MUF, also known as LINC00941, has emerged as a key player in oncogenic regulation, specifically implicated in the progression of various GI cancers, including esophageal, gastric, colorectal, hepatic, and pancreatic cancer. This review aims to provide an updated and focused analysis of the regulatory roles of LINC00941 in the initiation and progression of GI cancer. Our objective is to unravel the underlying molecular mechanisms through which LINC00941 influences GI cancer phenotypes both in vivo and in vitro, with a special emphasis on the key molecules and signaling pathways involved. Additionally, LINC00941 has demonstrated clinical significance in terms of clinical pathology, prognosis, and diagnosis in GI tumors, further reinforcing its potential as a novel therapeutic target.

show abstract